Auxogyn early embryo viability assessment test expands in Europe

Eeva test has been designed to improve the vitro fertilization (IVF) outcomes by assessing the viability of the embryo.

The test measures various cell-division parameters, which are scientifically and clinically validated from video images leveraging computer vision software.

Auxogyn president and chief executive officer Lissa Goldenstein said, "Our goal in developing Eeva is to help patients achieve a successful pregnancy. We expect that the availability of Eeva will help IVF clinics optimize the treatment path for their patients who are undergoing IVF procedures."

According to the company, the IVF test is first of its kind to accurately select potent embryos capable of entering into the blastocyst stage, which is crucial in embryo development.